Magellan Health Inc., which has created Click Therapeutics and Digital Therapeutic solutions, today announced a digital, integrated and comprehensive smoking cessation program.
The pharmacy benefit management (PBM) in combination with Click’s technology and machine learning will serve to perpetuate this endeavor. The full program, including access to a real-time data analytics portal, will be available to Magellan’s employer, managed care and government customers.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
CLICKOTINE is a comprehensive smoking cessation platform that works in tandem with Magellan’s resources, including access to live coaching, a clinical call center and PBM resources to provide quit aids, including nicotine replacement therapy.
By using this platform, people can have more tools to effectively take control of their health and overcome nicotine addiction.
Dr. Seth Feuerstein, chief medical officer of medical and digital innovation at Magellan Health, will join Click Therapeutics’ board of directors.
Feuerstein is a member of the Advisory Board at the Center for Biomedical and Interventional Technology at Yale University, as well as a member of the Yale University School of Medicine clinical faculty.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Photo: Flickr user Qfamily
